Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002975 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy in Treating Patients With Skin Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00002975 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 180 participants.
The verdict
NCT00002975, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic acid works in treating patients with skin cancer.
Interventions
- DRUG aminolevulinic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 1997-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002975
The ClinicalTrials.gov registry entry for NCT00002975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aminolevulinic acid is the first listed.
NCT00002975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002975 about?
NCT00002975 is a clinical study titled "Photodynamic Therapy in Treating Patients With Skin Cancer". RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic t...
What is the current status of trial NCT00002975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 1997-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00002975?
The interventions under investigation include: aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT00002975?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.